{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:17Z","timestamp":1760121317233},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.taap.2005.03.004","type":"journal-article","created":{"date-parts":[[2005,4,24]],"date-time":"2005-04-24T11:15:59Z","timestamp":1114341359000},"page":"210-221","source":"Crossref","is-referenced-by-count":31,"title":["Statins and PPAR\u03b1 agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment"],"prefix":"10.1016","volume":"208","author":[{"given":"Timothy E.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane R.","family":"Umbenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2005.03.004_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0002-9149(97)00430-X","article-title":"Safety and efficacy of long-term statin\u2013fibrate combinations in patients with refractory familial combined hyperlipidemia","volume":"80","author":"Athyros","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.taap.2005.03.004_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2005.03.004_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.taap.2005.03.004_bib4","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1074\/jbc.274.10.6718","article-title":"Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects","volume":"274","author":"Berger","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2005.03.004_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbt.10","article-title":"Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A","volume":"15","author":"Bleicher","year":"2001","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.taap.2005.03.004_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.43.100901.140223","article-title":"Hormesis: the dose\u2013response revolution","volume":"43","author":"Calabrese","year":"2003","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2005.03.004_bib7","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1210\/me.2003-0151","article-title":"The peroxisome proliferator-activated receptor beta\/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells","volume":"17","author":"Dressel","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.taap.2005.03.004_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002018-200225090-00004","article-title":"Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?","volume":"25","author":"Evans","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2005.03.004_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2796.2000.00646.x","article-title":"Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety","volume":"247","author":"Gavish","year":"2000","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.taap.2005.03.004_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1248\/bpb.21.1142","article-title":"Comparison of the effects of gemfibrozil and clofibric acid on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes","volume":"21","author":"Hashimoto","year":"1998","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.taap.2005.03.004_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0005-2760(92)90258-W","article-title":"The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid","volume":"1128","author":"Haughom","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2005.03.004_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4274(02)00010-3","article-title":"Myopathy and rhabdomyolysis with lipid-lowering drugs","volume":"128","author":"Hodel","year":"2002","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.taap.2005.03.004_bib13","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1210\/jc.86.7.3108","article-title":"Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis","volume":"86","author":"Hornung","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.taap.2005.03.004_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/bbrc.2001.6141","article-title":"Fibrate and statin synergistically increase the transcriptional activities of PPARalpha\/RXRalpha and decrease the transactivation of NFkappaB","volume":"290","author":"Inoue","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2005.03.004_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0960-0760(01)00027-9","article-title":"Peroxisome proliferators and fatty acids negatively regulate liver X receptor-mediated activity and sterol biosynthesis","volume":"77","author":"Johnson","year":"2001","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.taap.2005.03.004_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","article-title":"Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone","volume":"200","author":"Johnson","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2005.03.004_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s001250050048","article-title":"Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action","volume":"43","author":"Loviscach","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.taap.2005.03.004_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I","volume":"107","author":"Martin","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2005.03.004_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1211\/002235703765951401","article-title":"Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis","volume":"55","author":"Matzno","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.taap.2005.03.004_bib19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1248\/bpb.25.1509","article-title":"A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates","volume":"25","author":"Motojima","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.taap.2005.03.004_bib20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1248\/bpb.26.954","article-title":"Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice","volume":"26","author":"Motojima","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.taap.2005.03.004_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000063326","article-title":"Lipid-lowering drugs: are adverse effects predictable and reversible?","volume":"97","author":"Muscari","year":"2002","journal-title":"Cardiology"},{"key":"10.1016\/j.taap.2005.03.004_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2005.03.004_bib33","first-page":"72","article-title":"The statistical sleuth: a course in methods of data analysis","author":"Ramsey","year":"2002"},{"key":"10.1016\/j.taap.2005.03.004_bib23","doi-asserted-by":"crossref","first-page":"34967","DOI":"10.1074\/jbc.274.49.34967","article-title":"Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase","volume":"274","author":"Reszka","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2005.03.004_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/mol.59.2.193","article-title":"Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation","volume":"59","author":"Reszka","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2005.03.004_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bcp.2003.09.006","article-title":"Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression","volume":"67","author":"Ruiz Velasco","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2005.03.004_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin\u2013fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.taap.2005.03.004_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/bbrc.1999.1968","article-title":"Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells","volume":"267","author":"Shu","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2005.03.004_bib27","first-page":"1225","article-title":"HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies","volume":"257","author":"Smith","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2005.03.004_bib28","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/en.142.10.4189","article-title":"Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes","volume":"142","author":"Son","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.taap.2005.03.004_bib29","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.taap.2005.03.004_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2005.03.004_bib31","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X05001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X05001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T10:22:29Z","timestamp":1550226149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X05001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0041008X05001298"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2005.03.004","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}